Graham Johnson

Graham Johnson is the current President of Oricula Therapeutics and has over 30 years of experience in the pharmaceutical industry. Graham has held various positions of increasing responsibility, including VP of Discovery Chemistry at Bristol-Myers Squibb and Chief Research Officer at Rib-X Pharmaceuticals. At Oricula Therapeutics, Graham is responsible for leading the company's research and development efforts.

Graham has a long history of success in the pharmaceutical industry. Graham played a key role in the development of several blockbuster drugs, including Parke-Davis' blockbuster antidepressant, Zoloft. Graham's work has helped to improve the lives of millions of people around the world.

A native of the United Kingdom, Graham received their undergraduate degree from the University of Oxford and their PhD from Imperial College London. Graham has authored numerous scientific papers and holds several patents.

Graham Johnson has a Ph.D in New Reactions of Penicillins and Cephalosporins from Heriot-Watt University. Graham also has a B.Sc in Chemistry from the same school. Graham did postdoctoral research in Organic Chemistry at the Research Institute of Medicine and Chemistry, Imperial College London, and the Massachusetts Institute of Technology.

Their manager is Malcolm Gleser, CEO. They are on a team with Henry Ou - University of Washington, Assoc Professor, Marc Bailie - Chief Development Officer, INDS, and David W. Raible - University of Washington, Professor.